Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability

ACS Medicinal Chemistry Letters

Volumn 7, Issue 4, 2016, Pages 424-428

  Kinney, William A ^a   McDonnell, Mark E ^a,c   Zhong, Hua Marlon ^b   Liu, Chaomin ^b   Yang, Lanyi ^b   Ling, Wei ^b   Qian, Tao ^b   Chen, Yu ^b   Cai, Zhijie ^b   Petkanas, Dean ^a   Brenneman, Douglas E ^a  

^a KannaLife Sciences   (United States)

^b PharmaAdvance   (China)

^c Fox Chase Chemical Diversity Center   (United States)

Author keywords

cannabidiol; hepatic encephalopathy; neuroprotection

Indexed keywords

ALCOHOL; AMMONIUM ACETATE; CANNABIDIOL; HYDROGEN; KLS 3019; NEUROPROTECTIVE AGENT; RESORCINOL DERIVATIVE; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; EMBRYO; HIPPOCAMPAL NEURONAL CULTURE; HYDROGEN BOND; HYDROPHILICITY; IN VITRO STUDY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SURFACE AREA;

EID: 84965058055     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00009     Document Type: Article

References (19)

1. Córdoba, J. New assessment of hepatic encephalopathy J. Hepatol. 2011, 54, 1030-1040 10.1016/j.jhep.2010.11.015
2. Arias, N.; Méndez, M.; Fidalgo, C.; Aller, M. A.; Arias, J.; Arias, J. L. Mapping metabolic brain activity in three models of hepatic encephalopathy Int. J. Hypertens. 2013, 2013, 1-7 10.1155/2013/390872
3. Bailey, S. M.; Cunningham, C. C. Acute and chronic ethanol increases reactive oxygen species generation and decreases viability of isolated rat hepatocytes Hepatology 1998, 28, 1318-1326 10.1002/hep.510280521
4. 9-tetrahydrocahnnnabinol are neuroprotective antioxidants Proc. Natl. Acad. Sci. U. S. A. 1998, 95 (14) 8268-8273 10.1073/pnas.95.14.8268
5. Avraham, Y.; Grigoriadis, N. C.; Poutahidis, T.; Vorobiev, L.; Magen, I.; Ilan, Y.; Mechoulam, R.; Berry, E. M. Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice Br. J. Pharmacol. 2011, 162, 1650-1658 10.1111/j.1476-5381.2010.01179.x
6. Magen, I.; Avraham, Y.; Ackerman, Z.; Vorobiev, L.; Mechoulam, R.; Berry, E. M. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation J. Hepatol. 2009, 51, 528-534 10.1016/j.jhep.2009.04.021
7. Pazos, M. R.; Cinquina, V.; Gómez, A.; Layunta, R.; Santos, M.; Fernández-Ruiz, J.; Martínez-Orgado, J. Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function Neuropharmacology 2012, 63, 776-783 10.1016/j.neuropharm.2012.05.034
8. Hampson, A. J.; Grimaldi, M.; Lolic, M.; Wink, D.; Rosenthal, R.; Axelrod, J. Neuroprotective antioxidants from marijuana Ann. N. Y. Acad. Sci. 2000, 899, 274-282 10.1111/j.1749-6632.2000.tb06193.x
9. Hayakawa, K.; Mishima, K.; Fujiwara, M. Therapeutic potential of non-phschotropic cannabidiol in ischemic stroke Pharmaceuticals 2010, 3, 2197-2212 10.3390/ph3072197
10. 2+ levels J. Neurosci. 2009, 29 (7) 2053-2063 10.1523/JNEUROSCI.4212-08.2009
11. Ong, J. P.; Aggarwal, A.; Krieger, D.; Easley, K. A.; Karafa, M. T.; Van Lente, F.; Arroliga, A. C.; Mullen, K. D. Correlation between ammonia levels and the severity of hepatic encephalopathy Am. J. Med. 2003, 114, 188-193 10.1016/S0002-9343(02)01477-8
12. Bisogno, T.; Hanuš, L.; De Petrocellis, L.; Tchilibon, S.; Ponde, D. E.; Brandi, I.; Moriello, A. S.; Davis, J. B.; Mechoulam, R.; Di Marzo, V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide Br. J. Pharmacol. 2001, 134, 845-852 10.1038/sj.bjp.0704327
13. Wiley, J. L.; Beletskaya, I. D.; Ng, E. W.; Dai, Z.; Crocker, P. J.; Mahadevan, A.; Razdan, R. K.; Martin, B. R. Resorcinol derivatives: a novel template for the development of cannabinoid CB1/CB2 and CB2-selective agonists J. Pharmacol. Exp. Ther. 2002, 301, 679-689 10.1124/jpet.301.2.679
14. Hitchcock, S. A.; Pennington, L. D. Structure-Brain Exposure Relationships J. Med. Chem. 2006, 49, 7559-7583 10.1021/jm060642i
15. Jiang, R.; Yamaori, S.; Takeda, S.; Yamamoto, I.; Watanabe, K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes Life Sci. 2011, 89, 165-170 10.1016/j.lfs.2011.05.018
16. Harvey, D. J.; Martin, B. R.; Paton, W. D. M. Comparative in vivo metabolism of Δ1-tetrahydrocannabinol (Δ1-THC), cannabidiol (CBD) and cannabinol (CBN) by several species Recent Dev. Mass Spectrom. Biochem. Med. 1978, 1, 161-84 10.1007/978-1-4613-3991-5-13
17. Crombie, L.; Crombie, W. M. L.; Kilbee, G. W.; Tuchinda, P. Synthesis of 4″-carboxylated cannabinoids: stereospecific processes involving ethylidenemalonic ester Tetrahedron Lett. 1979, 49, 4773-4776 10.1016/S0040-4039(01)86707-1
18. Papahatjis, D. P.; Nahmias, V. R.; Nikas, S. P.; Andreou, T.; Alapafuja, S. O.; Tsotinis, A.; Guo, J.; Fan, P.; Makriyannis, A. C1′-Cycloalkyl side chain pharmacophore in tetrahydrocannabinols J. Med. Chem. 2007, 50, 4048-4060 10.1021/jm070121a
19. Ben-Shabat, S.; Hanuš, L. O.; Katzavian, G.; Gallily, R. New cannabidiol derivatives, synthesis, binding to cannabinoid receptor, and evaluation of their anti-inflammatory activity J. Med. Chem. 2006, 49, 1113-1117 10.1021/jm050709m